SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study
Shares of Sage Therapeutics, Inc. SAGE were down 4.3% on Oct. 8 after the company announced disappointing top-line data from the phase II LIGHTWAVE study, which evaluated its neuropsychiatric candidate,
Sage Therapeutics Phase 2 LIGHTWAVE Study In Alzheimer's Disease Fails; Stock Down In Pre-Market
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD) failed to meet the primary goal. The company's shares were down more than 12 percent in pre-market.
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%.
Sage Therapeutics Shares Fall Premarket After Alzheimer's Setback
Shares of Sage, which closed Monday at $6.72, were recently down 12% to $5.89 in premarket trading. Sage said Tuesday it is ending development of dalzanemdor in Alzheimer's disease after the compound didn't show a statistically significant difference versus placebo on the primary outcome measure of cognitive ability in a Phase 2 study in patients with mild cognitive impairment or mild dementia due to the memory-robbing disease.
Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment
The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.
bovnews2d
Lightwave Logic Inc (LWLG) Stock: More Strategic Than Meets the Eye
In recent trading, Lightwave Logic Inc (LWLG) stock price has shown some volatility, fluctuating 8.55% over the last five trades and 11.88% over the past 30 trades. This represents a notable shift ...
BioSpace5d
Sage Suffers Third Neuro Stumble in Six Months With Disappointing Mid-Stage Alzheimer’s Readout
Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...
Harnessing quantum principles: Phased arrays within phased arrays for smarter, greener indoor optical wireless networks
Imagine a future where indoor wireless communication systems handle skyrocketing data demands and do so with unmatched ...
Sage Therapeutics stock drops after disappointing Alzheimer's trial results
Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results ...
pharmaphorum5d
Sage takes another hit as Alzheimer's drug is canned
Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...
Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Sage Therapeutics is a sell due to failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's ...
bovnews12d
Lightwave Logic Inc (LWLG) Stock’s -0.37% Decrease This Year: What’s the Story?
On Monday, Lightwave Logic Inc (LWLG) stock saw a decline, ending the day at $2.76 which represents a decrease of $-0.19 or -6.44% from the prior close of $2.95. The stock opened at $2.95 and touched ...
Sage Therapeutics price target lowered to $8 from $9 at Wedbush
Wedbush lowered the firm’s price target on Sage Therapeutics to $8 from $9 and keeps a Neutral rating on the shares. The firm ...